

Ref: BHL/ STEX 59/ 2025-26

Date: January 16, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001 <b>Scrip Code: 539872</b>	National Stock Exchange of India Limited 5 <sup>th</sup> Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 <b>Symbol: BAJAJHCARE</b>
--	--

**Sub: Outcome of Board Meeting held on January 16, 2026**

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“Listing Regulations”) we hereby inform you that the Board of Directors of our Company at its meeting held today i.e. January 16, 2026, has considered and approved the followings:

1. Un-audited Financial Results of the Company for the quarter and nine months ended December 31, 2025 along with the Limited Review Report thereon issued by Walker Chandiook & Co. LLP, Statutory Auditors of the Company in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the same is attached herewith as an **Annexure A**.
2. Re-Appointment of Mr. Sajankumar Rameshwarlal Bajaj (DIN: 00225950) as Chairman & Managing Director of the Company for the period of three years with effect from April 01, 2026 to March 31, 2029, subject to the approval of the Shareholders of the Company.
3. Re-Appointment of Mr. Anil Champalal Jain (DIN: 00226137) as Managing Director of the Company for the period of three years with effect from April 01, 2026 to March 31, 2029, subject to the approval of the Shareholders of the Company.
4. Re-Appointment of Ms. Namrata Sajankumar Bajaj (DIN: 05327071) as Whole-Time Director of the Company for the period of three years with effect from April 01, 2026 to March 31, 2029, subject to the approval of the Shareholders of the Company.
5. Re-Appointment of Mr. Pakshal Anil Jain (DIN: 08776385) as Whole-Time Director of the Company for the period of three years with effect from June 30, 2026 to June 29, 2029, subject to the approval of the Shareholders of the Company.
6. Notice of Postal Ballot pursuant to Section 108 and 110 of the Companies Act, 2013 read with the rules made thereunder.

Mr. Sajankumar Rameshwarlal Bajaj, Mr. Anil Champalal Jain, Ms. Namrata Sajankumar Bajaj and Mr. Pakshal Anil Jain are not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority in accordance with BSE Circular No. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CML/2018/24 dated 20<sup>th</sup> June 2018.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024 are given in **Annexure B**.

We wish to inform you that the Board Meeting commenced today at 4.15 p.m. and concluded at 5.00 p.m.

Kindly take the same on record.

Thanking you.  
Yours faithfully,

**For and on behalf of Bajaj Healthcare Limited**

**Monica Tanwar**  
**Company Secretary & Compliance Officer**  
**Encl: as above**

**BAJAJ HEALTHCARE LIMITED**

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604

Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com

CIN No. L99999MH1993PLC072892

---

Walker ChandioK & Co LLP  
16th Floor, Tower III,  
One International Center,  
S B Marg, Prabhadevi (W),  
Mumbai - 400013  
Maharashtra, India  
T +91 22 6626 2600

**Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Bajaj Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Bajaj Healthcare Limited ('the Company') for the quarter ended 31 December 2025 and the year to date results for the period 01 April 2025 to 31 December 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Walker ChandioK & Co LLP**  
Chartered Accountants  
Firm Registration No: 001076N/N500013



**Yashwant M. Jain**  
Partner  
Membership No. 118782

**UDIN: 26118782BXYFLU7750**

**Place: Mumbai**  
**Date: 16 January 2026**

**BAJAJ HEALTHCARE LIMITED**

(CIN No.: L99999MH1993PLC072892)

(Reg. and Corp. Office: 6th Floor, Bhoomi Velocity Infotech Park, Above ICICI Bank, Road No. 23, Wagle Industrial Estate, Thane (W) - 400 604)

(Tel: + 91-22-6617400, Email: investors@bajajhealth.com, Website: www.bajajhealth.com)

**UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025**

(Rs. In Lakhs except for Earnings Per Share)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31 Dec 2025	30 Sept 2025	31 Dec 2024	31 Dec 2025	31 Dec 2024	31 March 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>A. Continuing Operations</b>						
I. Revenue from operations	16,122.27	14,791.49	12,279.40	45,797.39	38,812.99	54,260.24
II. Other Income	164.71	165.29	237.19	417.77	583.28	1,940.44
<b>III. Total Income (I+II)</b>	<b>16,286.98</b>	<b>14,956.78</b>	<b>12,516.59</b>	<b>46,215.16</b>	<b>39,396.27</b>	<b>56,200.68</b>
<b>IV. Expenses</b>						
(a) Cost of materials consumed	6,940.90	7,480.50	7,267.27	21,409.89	20,661.81	30,710.90
(b) Changes in Inventories of Finished Good and Work-in-progress	1,128.63	(120.39)	(1,175.80)	2,078.55	(1,414.14)	(2,066.37)
(c) Employee benefits expense	1,558.66	1,650.87	1,465.29	4,645.15	4,135.23	5,705.83
(d) Finance Costs	588.35	555.87	550.85	1,666.79	2,182.86	2,790.44
(e) Depreciation and amortisation expense	720.11	708.21	685.05	1,991.97	2,038.68	2,791.78
(f) Other expenses	3,425.87	3,085.51	2,558.64	9,449.63	8,363.26	11,667.33
<b>Total Expenses</b>	<b>14,362.52</b>	<b>13,360.57</b>	<b>11,351.30</b>	<b>41,241.98</b>	<b>35,967.70</b>	<b>51,599.91</b>
<b>V. Profit before Exceptional Items and Tax Expense</b>	<b>1,924.46</b>	<b>1,596.21</b>	<b>1,165.29</b>	<b>4,973.18</b>	<b>3,428.57</b>	<b>4,600.77</b>
VI. Exceptional items	-	-	-	-	-	-
<b>VII. Profit Before Tax</b>	<b>1,924.46</b>	<b>1,596.21</b>	<b>1,165.29</b>	<b>4,973.18</b>	<b>3,428.57</b>	<b>4,600.77</b>
<b>VIII. Tax Expense</b>						
(a) Current tax	-	-	-	-	-	-
(b) Deferred Tax charge / (Benefit)	314.37	351.35	(331.27)	900.86	294.99	307.89
<b>Total Tax Expenses</b>	<b>314.37</b>	<b>351.35</b>	<b>(331.27)</b>	<b>900.86</b>	<b>294.99</b>	<b>307.89</b>
<b>IX. Profit after Tax from Continuing Operations</b>	<b>1,610.09</b>	<b>1,244.86</b>	<b>1,496.56</b>	<b>4,072.32</b>	<b>3,133.58</b>	<b>4,292.88</b>
<b>B. Discontinued Operations</b>						
X. Loss before Tax from Discontinued Operations (Refer note 4)	(57.08)	(179.00)	(117.73)	(281.51)	(313.08)	(401.11)
XI. Tax Credit of Discontinued Operations	(14.37)	(45.06)	206.71	(70.86)	(11.27)	(57.78)
<b>XII. Loss after Tax from Discontinued Operations</b>	<b>(42.71)</b>	<b>(133.94)</b>	<b>(324.44)</b>	<b>(210.65)</b>	<b>(301.81)</b>	<b>(343.33)</b>
<b>XIII. Profit for the period / year (IX + XII)</b>	<b>1,567.38</b>	<b>1,110.92</b>	<b>1,172.12</b>	<b>3,861.67</b>	<b>2,831.77</b>	<b>3,949.55</b>
<b>XIV. Other comprehensive Income</b>						
<b>Continuing Operations</b>						
(i) Items that will not be reclassified to profit or loss	25.00	25.00	(92.73)	75.00	(278.18)	183.09
(ii) Income tax relating to items that will not be reclassified to profit or loss	(6.29)	(6.30)	23.34	(18.88)	70.02	(46.08)
(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Other Comprehensive Income from Continuing Operations</b>	<b>18.71</b>	<b>18.70</b>	<b>(69.39)</b>	<b>56.12</b>	<b>(208.16)</b>	<b>137.01</b>
<b>Discontinued Operations</b>						
(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Other Comprehensive Income from Discontinued Operations</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Other Comprehensive Income for the Period / Year</b>	<b>18.71</b>	<b>18.70</b>	<b>(69.39)</b>	<b>56.12</b>	<b>(208.16)</b>	<b>137.01</b>
<b>XV. Total Comprehensive Income for the Period / Year (XIII + XIV)</b>	<b>1,586.09</b>	<b>1,129.62</b>	<b>1,102.73</b>	<b>3,917.79</b>	<b>2,623.61</b>	<b>4,086.56</b>
<b>XVI. Paid-up Equity Share Capital (Face Value Rs. 5 per share)</b>	<b>1,579.16</b>	<b>1,579.16</b>	<b>1,579.16</b>	<b>1,579.16</b>	<b>1,579.16</b>	<b>1,579.16</b>
<b>XVII. Other Equity</b>						<b>45,037.26</b>
<b>XVIII. EPS (Not Annualised except for the year ended 31 March 2025)</b>						
<b>Continuing Operations</b>						
(a) Basic EPS (in Rs.)	5.10	3.95	4.66	12.89	10.77	14.45
(b) Diluted EPS (in Rs.)	5.01	3.88	4.65	12.68	10.76	14.26
<b>Discontinued Operations</b>						
(a) Basic EPS (in Rs.)	(0.14)	(0.42)	(1.01)	(0.67)	(1.04)	(1.16)
(b) Diluted EPS (in Rs.)	(0.14)	(0.41)	(1.01)	(0.67)	(1.04)	(1.14)
<b>Total Operations</b>						
(a) Basic EPS (in Rs.)	4.96	3.53	3.65	12.22	9.73	13.29
(b) Diluted EPS (in Rs.)	4.87	3.47	3.64	12.01	9.72	13.12



**Notes :**

1. The above Financial Results of Bajaj Healthcare Limited (the 'Company') have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 16 January 2026. These results have been subjected to limited review by the Statutory auditors who have expressed an unmodified review conclusion.

2. The above un-audited financial results for the quarter and nine months ended 31 December 2025 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS), as prescribed under Section 133 of the Companies Act 2013 (Act) read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

3. The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals.

4. In the year ended 31 March 2024, the Board of Directors had approved to sale/disposal of undertaking/unit(s) on going concern basis, situated at plot no. N-92, L-9/3, T-30, MIDC Tarapur, Taluka- Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D-2/CH/42 & D-2/CH/43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2022 from Saraswat Bank) and plot no.E-62 and E-63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale/disposal under Ind AS 105 ("Non-current Assets Held for Sale and Discontinued Operations"). The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Considering these assets are held for sale, the assets have been recorded at their fair value on the date these assets has been classified as held for sale. Out of these, one unit situated at plot no. N-92 was sold during the Quarter ended 31 March 2024. The total value of assets classified as held for sale represents lower of carrying value or fair value.

The financial information from discontinued operations:

Particulars	Quarter Ended			Nine Months Ended		Year ended
	31 Dec 2025	30 Sept 2025	31 Dec 2024	31 Dec 2025	31 Dec 2024	31 March 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income (A)	(1.05)	0.05	65.40	1.10	95.88	58.07
Total Expenses (B)	56.03	179.05	183.13	282.61	408.96	459.18
Loss before Tax from Discontinued Operations (C = A - B)	(57.08)	(179.00)	(117.73)	(281.51)	(313.08)	(401.11)
Tax Credit from Discontinued Operations (D)	(14.37)	(45.06)	206.71	(70.86)	(11.27)	(57.78)
Loss after Tax from Discontinued Operations (E = C - D)	(42.71)	(133.94)	(324.44)	(210.65)	(301.81)	(343.33)

5. The Board of Directors of the Company in their meeting held on 10 July 2024 and the shareholders of the company in Extra-Ordinary General Meeting ("EGM") held on 07 August 2024 through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") approved, the issue of 40,44,852 Equity Shares at Rs 338 per share (including premium at Rs. 333 per share) to Person(s) belonging to non-promoter category on preferential basis and the issue of convertible equity warrants 20,79,409 at Rs. 338 per warrant (including premium at Rs. 333 per share) to Person(s) belonging to promoter category as well as non-promoter category on preferential basis. The object of the issue is to repayment of term loan, investment in capital expenditure and general corporate purposes. The Company has also obtained the in-principal approval of listing of equity shares from National Stock Exchange of India Ltd and BSE Ltd. On 19 September 2024, post approval from Board, the Company has allotted 39,84,852 no. of equity shares and 20,79,409 convertible warrants and has also filed the relevant form with Registrar of Companies, Mumbai. The uncalled amount of share warrants as at 31 December 2025 is Rs. 5,271.30 lakhs and will be received within 18 months from the allotment date of 19 September 2024.

6. The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities.

Particulars	Rs. (in Lakhs)
Repayment & prepayment of secured/unsecured loans from bank/NBFC	15,000.00
General corporate purposes	225.90
<b>Total</b>	<b>15,225.90</b>

7. In April 2025, the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) ("Genrx"), on a going concern basis. Genrx is an existing company incorporated under the provisions of the Companies Act, 1956. The acquisition was made for a total consideration of Rs. 1,085 lakhs. Subsequently, on 3 June 2025, the Company filed an application with the Hon'ble National Company Law Tribunal ("NCLT"), Mumbai, seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern, which is pending with NCLT as on 31 December 2025. Hence, Genrx has not been considered a subsidiary for consolidation purpose, pending requisite approvals from the NCLT, as control, defined under Ind AS 110 Consolidated Financial Statements is not established.



Date : 16 Jan 2026  
Place: Thane



For and on behalf of the Board  
For Bajaj Healthcare Limited

Mr. Anil C Jain  
D.No.: 00226137  
Managing Director

**BAJAJ**

Annexure B

**Disclosure pursuant to Para A of Part A of Schedule III of Regulation 30 of Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024**

**Re-Appointment of Executive Directors of the Company:**

<b>Requirement of Disclosure</b>	<b>Mr. Sajankumar Rameshwarlal Bajaj</b>	<b>Mr. Anil Champalal Jain</b>
<b>Reason for Change</b>	Re-Appointment as Chairman & Managing Director of the Company	Re-Appointment as Managing Director of the Company
<b>Date of Re-appointment &amp; Term of Re-appointment</b>	For the period of 3 years from April 01, 2026 to March 31, 2029, subject to the approval of shareholders of the Company	For the period of 3 years from April 01, 2026 to March 31, 2029, subject to the approval of shareholders of the Company
<b>Brief Profile</b>	Mr. Sajankumar Rameshwarlal Bajaj has been associated with the Company for more than three decades and holds a Bachelor's degree in Commerce. He possesses extensive experience in finance, marketing, and material procurement, which has significantly contributed to the Company's growth and enhanced its operational efficiency.	Mr. Anil Champalal Jain has completed his Diploma in Pharmacy and has been associated with the Company for more than three decades. He has played a pivotal role in overseeing the overall operations and has contributed significantly to the sustained growth and performance of the Company. With his strong marketing acumen, visionary leadership, and tireless efforts, he has been instrumental in driving business development, expanding market presence, and strengthening the Company's competitive position.
<b>Disclosure of relationship Between Directors (in case appointment of a Director)</b>	Father of Ms. Namrata Sajankumar Bajaj, Whole-Time Director of the Company	Father of Mr. Pakshal Anil Jain, Whole-Time Director of the Company

<b>Requirement of Disclosure</b>	<b>Ms. Namrata Sajankumar Bajaj</b>	<b>Mr. Pakshal Anil Jain</b>
<b>Reason for Change</b>	Re-Appointment as Whole-Time Director of the Company	Re-Appointment as Whole-Time Director of the Company
<b>Date of Re-appointment &amp; Term of Re-appointment</b>	For the period of 3 years from April 01, 2026 to March 31, 2029, subject to the approval of shareholders of the Company	For the period of 3 years from June 30, 2026 to June 29, 2029, subject to the approval of shareholders of the Company
<b>Brief Profile</b>	Ms. Namrata S. Bajaj holds a Bachelor's degree in Business Administration from the Indian Institute of Planning and Management, Mumbai. She has been associated with the Company for over 10 years and brings extensive experience in sales and marketing. Currently overseeing the Sales and Marketing functions of the Formulation Division, Ms. Bajaj has played a pivotal role in elevating the company's presence in the formulation business through her dedication and consistent efforts.	Mr. Pakshal Anil Jain holds a Bachelor's degree in Marketing & Entrepreneurship from the Indian School of Management & Entrepreneurship, Mumbai (ISME). He possesses sound knowledge of marketing of Active Pharmaceutical Ingredients (API) along with an understanding of formulation manufacturing. He has been associated with the Company for more than five (5) years and has developed strong expertise in marketing, particularly in the areas of API development and contract manufacturing, contributing to the Company's business growth and market expansion.
<b>Disclosure of relationship Between Directors (in case appointment of a Director)</b>	Daughter of Mr. Sajankumar R. Bajaj, Chairman & Managing Director of the Company	Son of Mr. Anil Champalal Jain, Managing Director of the Company

**BAJAJ HEALTHCARE LIMITED**

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604

Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com

CIN No. L99999MH1993PLC072892